Liposomal delivery systems for intestinal lymphatic drug transport

Biomaterials Research

Volumn 20, Issue 1, 2016, Pages

  Ahn, Hyeji ^a   Park, Ji Ho ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Chylomicron; First pass metabolism; Intestinal lymphatic transport; Lipid; Liposome

Indexed keywords

EID: 85006965105     PISSN: None     EISSN: 20557124     Source Type: Journal    
DOI: 10.1186/s40824-016-0083-1     Document Type: Review

References (36)

1. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Disc. 2003;2:289-95.
2. Charman WNA, Stella VJ. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986;34:175-8.
3. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Disc. 2007;6: 231-48.
4. Ali Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8: 2733-44.
5. Wasan KM, et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Disc. 2008;7:84-99.
6. Trevaskis NL, et al. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Disc. 2015;14:781-803.
7. Shi Y, Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Disc. 2004;3:695-710.
8. Porter CJH, et al. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001;50:61-80.
9. Redgrave TG. Chylomicron metabolism. Biochem Soc Trans. 2004;32:79-82.
10. Khoo S-M, et al. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001;90:1599-607.
11. Murakami M, et al. Enteral siRNA delivery technique for therapeutic gene silencing in the liver via the lymphatic route. Sci Rep. 2015;5:1-13.
12. Zhou C, et al. The preparation of a complex of insulin-phospholipids and their interaction mechanism. J Pept Sci. 2012;18:541-8.
13. Fricker G, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharma Res. 2010;27:1469-86.
14. Charman WN. Lipids, lipophilic drugs, and oral drug delivery-Some emerging concepts. J Pharm Sci. 2000;89:967-78.
15. Dahan A, et al. The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release. 2008;126:1-9.
16. Khan MSY, Akhter M. Glyceride derivatives as potential prodrugs: synthesis, biological activit y and kinetic studies of glyceride derivatives of mefenamic acid. Pharmazie. 2005;60:110-4.
17. Caliph SM, et al. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats. J Pharm Sci. 2000;89:1073-84.
18. Attili-Qadri S, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci U S A. 2013;110:17498-503.
19. Fang G, et al. Improved oral bioavailability of docetaxel by nanostructured lipid carriers: in vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv. 2015;5:437-96447.
20. Paliwal R, et al. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. J Pharm. 2009;29:181-8.
21. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Disc. 2005;5:145-60.
22. Yoo J-W, et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Disc. 2011;10:521-35.
23. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36-48.
24. Andar AU, et al. Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms. Pharm Res. 2014;31:401-13.
25. Kim H, et al. Liposomal formulations for enhanced lymphatic drug delivery. Asian J Pharm Sci. 2013;8:96-103.
26. Iwanaga K, et al. Oral delivery of insulin by using surface coating liposomes: Improvement of stability of insulin in GI tract. Int J Pharm. 1997;157:73-80.
27. Kisel MA, et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm. 2001;216:105-14.
28. Ling SSN, et al. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm. 2006; 32:335-45.
29. Niu M, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012;81:265-72.
30. Niu M, et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: A mechanistic study. Int J Pharm. 2014;460:119-30.
31. Huang Y-B, et al. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin. J Drug Target. 2011;19:709-18.
32. Li X, et al. Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake. Int J Nanomedicine. 2011;6:3151-62.
33. Takeuchi H, et al. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release. 2003;86:235-42.
34. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev. 2001;52:117-26.
35. Takeuchi H, et al. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res. 1996;13:896-901.
36. Kim HJ, Lee CM, Lee YB, et al. Preparation and mucoadhesive test of CSAloaded liposomes with different characteristics for the intestinal lymphatic delivery. Biotechnol Bioprocess Eng. 2005;10:516-21.